Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[41] Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan
Akakura, Koichiro
Uemura, Hiroji
Kawakami, Satoru
Yokomizo, Akira
Nakamura, Motonobu
Nishimura, Kazuo
Komori, Tetsushi
Ledesma, Dianne Athene
FUTURE ONCOLOGY, 2024, 20 (12) : 781 - 798
[42] Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Yong Du
Ignasi Carrio
Giuseppe De Vincentis
Stefano Fanti
Harun Ilhan
Caroline Mommsen
Egbert Nitzsche
Francis Sundram
Wouter Vogel
Wim Oyen
Val Lewington
European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1671 - 1678
[43] Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience
Costa, Renato P.
Bordonaro, Sebastiano
Cappuccio, Francesco
Tripoli, Vincenzo
Murabito, Alessandra
Licari, Maria
Valerio, Maria R.
Tralongo, Paolo
PROSTATE INTERNATIONAL, 2019, 7 (01) : 25 - 29
[44] Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
O'Sullivan, Joe M.
McKay, Rana R.
Rahbar, Kambiz
Fizazi, Karim
George, Daniel J.
Tombal, Bertrand
Schmall, Anja
Sandstrom, Per
Verholen, Frank
Shore, Neal
FRONTIERS IN MEDICINE, 2022, 9
[45] Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
Aprile, Carlo
Persico, Marco G.
Lodola, Lorenzo
Buroni, Federica E.
WORLD JOURNAL OF RADIOLOGY, 2016, 8 (10): : 816 - 818
[46] Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study
Sasaki, Daichi
Hatakeyama, Shingo
Kawaguchi, Hideo
Hatayama, Yoshiomi
Ishibashi, Yusuke
Kusaka, Ayumu
Noro, Daisuke
Tanaka, Toshikazu
Ito, Hiroyuki
Okuyama, Yoshiharu
Okamoto, Teppei
Yamamoto, Hayato
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Aoki, Masahiko
Ohyama, Chikara
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (02) : 64.e1 - 64.e8
[47] The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review
Pinto, Alvaro
Dominguez, Mario
Gomez-Iturriaga, Alfonso
Rodriguez-Vida, Alejo
Vallejo-Casas, Juan Antonio
Castro, Elena
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 210
[48] Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Matsubara, Nobuaki
Nagamori, Satsohi
Wakumoto, Yoshiaki
Uemura, Hirotsugu
Kimura, Go
Yokomizo, Akira
Kikukawa, Hiroaki
Mizokami, Atsushi
Kosaka, Takeo
Masumori, Naoya
Kawasaki, Yoshihide
Yonese, Junji
Nasu, Yasutomo
Fukasawa, Satoshi
Sugiyama, Takayuki
Kinuya, Seigo
Hosono, Makoto
Yamaguchi, Iku
Tsutsui, Hirokazu
Uemura, Hiroji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 173 - 180
[49] Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
Modi, Dipenkumar
Hwang, Clara
Mamdani, Hirva
Kim, Seongho
Gayar, Hesham
Vaishampayan, Ulka
Joyrich, Richard
Heath, Elisabeth I.
CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : 373 - 380
[50] Management of metastatic castration-resistant prostate cancer: A focus on radium-223 Opinions and suggestions from an expert multidisciplinary panel
Baldari, Sergio
Boni, Giuseppe
Bortolus, Roberto
Caffo, Orazio
Conti, Giario
De Vincentis, Giuseppe
Monari, Fabio
Procopio, Giuseppe
Santini, Daniele
Seregni, Ettore
Valdagni, Riccardo
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 113 : 43 - 51

← 1 2 3 4 5 →